BGNE BeiGene Ltd. Final Profit

Corporate emblem and logo of BeiGene (BGNE)

Fierce competition in biotechnology and patent battles are creating volatility, which the GURU.Markets terminal illustrates on the financial profit chart for BeiGene, Ltd. (BGNE). Business stability is based on a global presence in the US, Europe, and China, while the success of the drug Brukinsa is accelerating returns. The value of 0.65 represents the current metric level, confirming the resilience of operating capital.

BGNE (BeiGene, Ltd.) Net Profit history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company BeiGene (BGNE)

- stock value and consensus price forecast:
Market Price BeiGene Ltd|BGNE - Price Target Chart
- market capitalization data:
Market Value BeiGene Ltd|BGNE - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share BeiGene|BGNE - Book Capitalization|Market Cap to Net Assets Ratio beigene.com|BGNE - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital BeiGene, Ltd.|BGNE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital BeiGene Ltd.|BGNE - Company Aggregate Debts|Debts to Book Value BeiGene Ltd|BGNE - Company Long-Term Debts|Company Short-Term Debt BeiGene|Immediate Liquidity beigene.com
- net income and valuation multiples indicators:
BGNE - Net Profit
Fundamental valuation:BGNE BeiGene Ltd
Manufactured product of BeiGene Ltd.

BeiGene, Ltd. (BGNE) operations amid the geopolitical confrontation between the US and China create significant regulatory risks for oncology drug supply chains. This metric tracks the daily dynamics of net operating profit, excluding management's accounting manipulations and identifying real profitability peaks, which allows the investor to objectively assess business resilience through the company's profit history.

Direct competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Profit ARAY|Company Net Income SLS (sellaslifesciences.com)|Net Profit ACTU (Actuate Therapeutics)|Citius Oncology Inc. (CTOR) - Company Net Income|TuHURA - Net Profit|Net Financial Result Protara Tx TARA|FATE: Net Profit|Annual Net Income Aadi Bioscience WHWK|TCRX (TScan Therapeutics Inc) - Net Profit|Company Net Income Champions Oncology Corp CSBR|Company Net Income XBiotech Inc. (XBIT)|cel-sci.com - Company Profit|Net Profit OSTX (OS Therapies Incorporated)|Radiopharm Theranostics Ltd (RADX) - Company Net Income|ARTV: Net Income|Final Profit ANL (Adlai Nortye Ltd.)|Veru Pharma (VERU) - Company Net Income|TPST (Tempest Therapeutics Corp) - Company Net Income|Net Income XLO|RENB (Enochian BioSciences) - Profit After Payment of Taxes|Net Profit MURA|kairospharma.com - Company Profit|OnKure Therapeutics - Net Income|Net Financial Result CytoMed Therapeutics Ltd (GDTC)|Curis Corp - Net Profit|APLM: Company Net Income|THAR: Net Profit|Annual Net Income Advanced Biomed ADVB|Company Net Income Genprex, Inc|Company Profit CLDI (Calidi Bio)|Net Profit SBFM|XBIO - Company Net Income|Net Profit SLRX (Salarius Pharmaceuticals, Inc.)|PPBT - Net Income|AON - Net Profit|CKPT - Net Profit|Elevation Oncology, Inc. (ELEV) - Company Net Income|Company Profit ICAD|IKNA (Ikena Oncology Inc.) - Net Profit|Net Income Notable Labs Ltd (NTBL)|Net Profit VIRX|MOR - Company Net Income|Company Net Income NAYA Biosciences NAYA|Final Profit AAPGV